RA
SCLN

Royce & Associates’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Royce & Associates’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-717
Closed -$8K – 1308
2017
Q3 		$8K Buy
+717
New +$7.91K ﹤0.01% 1200
2015
Q4 		– Sell
-5,000
Closed -$35K – 1217
2015
Q3 		$35K Hold
5,000
– – ﹤0.01% 1173
2015
Q2 		$49K Hold
5,000
– – ﹤0.01% 1178
2015
Q1 		$44K Hold
5,000
– – ﹤0.01% 1196
2014
Q4 		$44K Hold
5,000
– – ﹤0.01% 1268
2014
Q3 		$34K Sell
5,000
-10,100
-67% -$60.5K ﹤0.01% 1366
2014
Q2 		$79K Hold
15,100
– – ﹤0.01% 1357
2014
Q1 		$69K Buy
15,100
+1,400
+10% +$6.76K ﹤0.01% 1359
2013
Q4 		$69K Hold
13,700
– – ﹤0.01% 1373
2013
Q3 		$69K Buy
13,700
+2,000
+17% +$11.1K ﹤0.01% 1385
2013
Q2 		$58K Buy
+11,700
New +$55.7K ﹤0.01% 1370

Royce & Associates's SCLN Position: Q4 2017 in Review

Royce & Associates sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 717 shares — an estimated $8K sold.

Royce & Associates first reported a position in SCLN in Q2 2013 and held it in 11 quarters. The position peaked at $79K in Q2 2014. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Royce & Associates reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Royce & Associates sold 717 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $8K.
  • Royce & Associates first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 11 quarters.
  • Royce & Associates's Sciclone Pharmaceuticals Inc position peaked at $79K in Q2 2014.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Royce & Associates's 13F filing for Q4 2017, filed 9 Feb 2018.